---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-22-185058"
form_type: "8-K"
ticker: "ANTX"
cik: "0001880438"
company_name: "AN2 Therapeutics, Inc."
filed_at: "2022-06-29T23:59:59+00:00"
generated_at: "2026-06-24T22:28:05.635710+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# AN2 screens first patient in pivotal Phase 2/3 trial of epetraborole for refractory MAC lung disease

## Summary
- Epetraborole is a once-daily oral therapy with novel MOA for treatment-refractory MAC lung disease, the most common NTM lung disease.
- Phase 2/3 adaptive trial (EBO-301) targets ~314 patients; Phase 2 topline expected mid-2023, Phase 3 mid-2024.
- Epetraborole has FDA QIDP, Fast Track, and Orphan Drug designations; plans to use LPAD pathway for streamlined approval.
- First patient screened; Phase 2 will assess clinical response, safety, and PK to inform Phase 3 design.

## SEC filing metadata
- accession: 0001193125-22-185058
- form_type: 8-K
- ticker: ANTX
- cik: 0001880438
- company_name: AN2 Therapeutics, Inc.
- filed_at: 2022-06-29T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1880438/000119312522185058/0001193125-22-185058-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1880438/000119312522185058/d322412d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-22-185058
- JSON: https://secwatch.observer/filing/0001193125-22-185058.json
- Plain text: https://secwatch.observer/filing/0001193125-22-185058.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.